ClinicalTrials.gg
Enrolling by invitationNCT06891053TIARAUpdated Oct 28, 2026

Studio TIARA: Alessitimia ed Emicrania Cronica

An observational study in Migraine and Alexithymia, sponsored by Azienda Sanitaria Locale di Alessandria. Enrolling by invitation at 1 site in Italy. Open to female participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Azienda Sanitaria Locale di Alessandria · Observational

How we know

Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
350
Ages
12 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.

Planned enrollment
11th of 42
350 · median 108
Started
2022
with 11 others
Observational
42 of 115
26 open now
Primary completion
2027-06
later than 35 of 46 live
Registered
102nd of 115
by date

Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 11th largest by planned enrollment of the 42 observational ones that give a count, is one of 12 that started in 2022, is one of 42 observational ones, reaches primary completion later than 35 of the 46 other live ones, and was the 102nd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 12 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Migraine Disorders with a site in Italy, or all of them as a file.
02

Study summary

The aim of this observational, cross-sectional study is to investigate the relationship between alexithymia and migraine frequency (considering alexithymia a condition that can influence the severity of the clinical phenotype of migraine, favoring its chronicization), in an analysis adjusted for psychiatric comorbidity (for anxiety and depression, potentially influencing migraine chronicization) and for personalogical factor represented by apathy.

03

Conditions studied

  • Migraine
  • Alexithymia
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female patients, aged 12-65 years, diagnosed with episodic migraine with or without aura, chronic migraine and/or MOH according to ICHD-3 2018 criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of episodic migraine with or without aura, chronic migraine and/or MOH according to ICHD-3 2018 criteria;
  • Patients aged 12-65 years;
  • Female patients

Exclusion criteria

Exclusion Criteria:

  • Ongoing major depressive episode;
  • Comorbidities for major internal diseases (hepatopathy, nephropathy, heart failure, etc.);
  • Alcohol or substance abuse disorder (eoin, cocaine, cannabis, hallucinogens);
  • Language barrier;
  • Low cultural/cognitive level;
  • No .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diagnosis of episodic migraine without or with aura, chronic migraine, and/or MOH

    Female patients, aged 12-65 years, diagnosed with episodic migraine without or with aura, chronic migraine, and/or MOH according to the criteria of ICHD-3 2018

06

What researchers measure

Primary outcomes

  1. Degree of alexithymia

    Independent variable measured as a score on the TAS-20 scale

    Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval

  2. Migraine frequency

    Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval

Secondary outcomes

  1. Number of "drug days" in patients diagnosed with MOH

    Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval

  2. Degree of alessithymia in patients diagnosed with MOH

    Time frame: In 3 periods of 30 days each (3 months), which make up the 90-day observation time interval

07

Study locations

1 site
  • Azienda Sanitaria Locale di Alessandria (ASL AL)
    Alessandria, Italy 15121, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2025 → Jun 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 24, 2025
StartActual
May 30, 2022
Primary completionEst.
Jun 2027was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Jun 2027
Oct 28, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Dec 2025→Jun 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06891053
Lead sponsor
Azienda Sanitaria Locale di Alessandria
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
May 30, 2022
Primary completion
Jun 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Eugenia Rota
principal investigator · Azienda Sanitaria Locale di Alessandria (ASL AL)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion